NGS is the most transformative technology in the history of clinical diagnostics — enabling simultaneous analysis of thousands of genes from a single patient sample, detecting mutations that single-gene tests miss, and unlocking precision medicine at scale. The clinical NGS market is growing at a 14.5% CAGR — the fastest in IVD — driven by oncology, rare disease, infectious disease, and prenatal testing. Illumina dominates the sequencing instrument market but faces emerging competition from Oxford Nanopore and PacBio in long-read sequencing. Roche, Thermo Fisher, and QIAGEN supply the reagent kits, bioinformatics pipelines, and clinical workflows that make NGS routine. The regulatory path from research to clinical use — FDA 510(k), PMA, and the EU IVDR Class D classification — is still a barrier for many applications but is progressively being cleared as clinical validation evidence accumulates.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• NGS in Diagnostics Market Size and Forecast 2025-2030 by Application and Region
• Oncology NGS — Tumor Profiling, Companion Diagnostics, and Liquid Biopsy
• Rare Disease and Genetic Testing — Whole Genome Sequencing and Exome Analysis
• Infectious Disease NGS — Pathogen Identification, AMR Detection, and Outbreak Surveillance
• Prenatal and Reproductive NGS — NIPT, PGT, and Carrier Screening
• Sequencing Platforms — Short-Read, Long-Read, and Nanopore Technologies
• Bioinformatics and Clinical Interpretation — Software, AI, and Data Management
• Regulatory Pathway — FDA, EU IVDR, and Global Approval Strategy for NGS Tests
• Competitive Landscape — Illumina, Roche, Thermo Fisher, QIAGEN, Oxford Nanopore
• Investment and Partnership Opportunities — Platform Access, Reagent Supply, and Data Partnerships
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Highest-priority NGS clinical opportunities
- Competitive landscape summary
- Strategic recommendations
2. Market Overview
- Market definition, scope and segmentation
- Key demand drivers and restraints
- Regulatory pathways — FDA, EU IVDR Class D, and global frameworks
3. Oncology NGS
- Tumor profiling and somatic mutation testing
- Companion diagnostics and co-development with pharma
- Liquid biopsy integration with tissue-based NGS
4. Rare Disease and Genetic Testing
- Whole genome sequencing for rare disease diagnosis
- Exome analysis and gene panel testing
- Newborn sequencing programs
5. Infectious Disease NGS
- Pathogen identification from clinical samples
- Antimicrobial resistance gene detection
- Metagenomics and outbreak surveillance
6. Prenatal and Reproductive NGS
- Non-invasive prenatal testing
- Preimplantation genetic testing
- Expanded carrier screening
7. Sequencing Platforms and Bioinformatics
- Short-read, long-read, and nanopore platform comparison
- Bioinformatics infrastructure and AI-assisted variant classification
- Data management and clinical reporting
8. Competitive Landscape
- Illumina, Roche, Thermo Fisher, QIAGEN, Oxford Nanopore, and MGI Tech
- New entrants and emerging platforms
- M&A and partnership activity 2023-2025
9. Regional Market Analysis
- 9.1 North America (U.S., Canada, Mexico)
- 9.2 Europe (38 countries)
- 9.3 Asia-Pacific (18 countries)
- 9.4 Latin America (22 countries)
- 9.5 Middle East (11 countries)
- 9.6 Africa and Rest of World
10. Investment and Partnership Opportunities
- Platform access and reagent supply partnerships
- Bioinformatics and data management investments
- Startup and emerging company ecosystem
11. Strategic Conclusions and Recommendations
- Highest-priority NGS opportunities by application and region
- Market entry and expansion strategies
- M&A, partnership and investment priorities
12. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. NGS in Diagnostics — Application Landscape and Technology Status 2025
Table 2. Oncology NGS — Application Summary and Leading Suppliers 2025
Table 3. Rare Disease and Genetic Testing — Application Summary 2025
Table 4. Infectious Disease NGS — Application Summary and Leading Suppliers 2025
Table 5. Prenatal and Reproductive NGS — Application Summary 2025
Table 6. Sequencing Platform Comparison — Short-Read, Long-Read, and Nanopore 2025
Table 7. Leading Suppliers and Competitive Positioning — NGS in Diagnostics 2025
Table 8. M&A and Partnership Activity in Clinical NGS 2023-2025
Table 9. Regulatory Pathway Summary by Application and Region 2025
Table 10. Investment Opportunity Assessment by NGS Application
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
